Schizophrenia risk genes: Implications for future drug development and discovery

Garret O'Connell, Stephen M Lawrie, Andrew M McIntosh, Jeremy Hall

Research output: Contribution to journalArticlepeer-review


Present-day development of improved treatments for schizophrenia is hindered by uncertain models of disease, inter-individual response variability in clinical trials and a paucity of sensitive measures of treatment effects. Findings from genetic research emphasize the potential for schizophrenia risk genes to help develop focused treatments, discover new drug targets and provide markers of clinical subtypes. Advances in genetic technologies also provide novel modes of drug discovery in schizophrenia such as transcriptomics, epigenetics and transgenic animal models. In this review, we discuss proven and proposed ways risk genes can be used to enhance the development and discovery of treatments for schizophrenia and highlight key studies in these approaches.
Original languageEnglish
Pages (from-to)1367-73
Number of pages7
JournalBiochemical Pharmacology
Issue number12
Publication statusPublished - 2011

Fingerprint Dive into the research topics of 'Schizophrenia risk genes: Implications for future drug development and discovery'. Together they form a unique fingerprint.

Cite this